Antiasthmatic CAS151767-02-1 Montelukast Sodium Powder Montelukast Sodium

• Customization: Available
• CAS No.: 151767-02-1
• Formula: C35h35clnnao3s
• Model NO.: QS-Montelukast Sodium
• EINECS: 604-813-7
• Packaging Material: Negotiable
• Storage Method: Normal
• Shelf Life: >12 Months
• Nutrient Composition: Montelukast Sodium
• Resource: Montelukast Sodium
• The content of active substances: >99%
• Product Name: Montelukast Sodium
• Name: Montelukast Sodium Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Grade
• Assay: >99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Mf: C35h35clnnao3s
• MW: 608.169
• Refractive Index: 1.538
• Boiling Point: 760mmhg
• Storage Tempera: 2-8c
• Melting Point: 84-90c
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Montelukast Sodium
• Origin: Xi`an
• Production Capacity: 1000kg/Month

Product Description

Antiasthmatic CAS151767-02-1 Montelukast sodium Powder Montelukast sodium

Product Description

Product Details

Product name	Montelukast Sodium
Cas number	151767-02-1
Appearance	White powder
MF	C35H35ClNNaO3S
MW	608.169

Montelukast Sodium is a highly potent and selective antagonist of the CysLT1 receptor (with an IC50 of less than 5 nM), exhibiting no significant effect on the CysLT2 receptor. It functions by competitively inhibiting leukotrienes, particularly LTD4, a key mediator involved in pulmonary and immune system pathways. In studies on rat colitis, Montelukast Sodium has been shown to enhance PGE2 (Prostaglandin E2) production while reducing COX-2 expression. Due to its specific mechanism of action, it is not effective for treating acute asthma attacks but is suitable for long-term management. Additionally, it does not interfere with other asthma medications like theophylline. Another drug in the same class is zafirlukast (Accolate), which also targets leukotriene receptors.

Application&Function

Montelukast is a potent oral leukotriene receptor antagonist that effectively improves asthma inflammation by inhibiting leukotrienes, which are released during inflammatory responses like allergen exposure. It selectively targets type I cysteinyl leukotriene receptors (CysLT1), blocking the effects of inflammatory mediators (LTC4, LTD4, LTE4) without agonist activity. Clinically, it is used for the prevention and long-term treatment of asthma in patients aged 15 and older, including daytime and nighttime symptoms, aspirin-sensitive asthma, and exercise-induced bronchoconstriction. It also alleviates symptoms of seasonal allergic rhinitis, such as sneezing, nasal congestion, runny nose, and itching.

Specification